文献速递浆细胞疾病

通过全基因组规模CRISPR-Cas9筛选鉴定COQ2作为骨髓瘤细胞增殖和脂质过氧化的调控因子

Identification of COQ2 as a regulator of proliferation and lipid peroxidation through genome-scale CRISPR-Cas9 screening in myeloma cells.
PubMed 文献 · Br J Haematol · 2024-03-10

研究采用全基因组CRISPR-Cas9功能缺失筛选鉴定骨髓瘤潜在治疗靶点,发现COQ2调控骨髓瘤细胞增殖和脂质过氧化。COQ2敲除抑制细胞增殖、诱导细胞周期阻滞并减少体内肿瘤生长,机制上COQ2促进MEK/ERK级联激活进而稳定激活MYC蛋白。COQ2缺陷细胞对脂质过氧化激活剂RSL3敏感性增加,4-CBA联合RSL3可诱导硼替佐米耐药骨髓瘤细胞死亡。

要点

  • 全基因组CRISPR-Cas9筛选鉴定COQ2为骨髓瘤细胞增殖和脂质过氧化的调控因子。
  • COQ2敲除抑制细胞增殖、诱导细胞周期阻滞并减少体内肿瘤生长。
  • COQ2通过激活MEK/ERK/MYC轴促进增殖,靶向COQ2可增强骨髓瘤细胞对铁死亡的敏感性。

核心结论

  • COQ2通过激活MEK/ERK/MYC轴促进骨髓瘤细胞增殖和肿瘤生长。
  • 靶向COQ2可增强骨髓瘤细胞对铁死亡的敏感性,可能是骨髓瘤患者有前景的治疗策略。

研究设计与样本

  • 研究采用全基因组CRISPR-Cas9功能缺失筛选鉴定骨髓瘤潜在治疗靶点。
  • 研究在骨髓瘤细胞中敲除COQ2,检测细胞增殖、细胞周期和体内肿瘤生长。
  • 研究使用COQ2抑制剂4-CBA联合RSL3处理原代CD138+骨髓瘤细胞和异种移植小鼠模型。
  • 研究在硼替佐米耐药骨髓瘤细胞中检测4-CBA与RSL3联合处理的细胞死亡。

主要发现

  • COQ2敲除抑制细胞增殖、诱导细胞周期阻滞并减少体内肿瘤生长。
  • COQ2促进MEK/ERK级联激活,进而稳定并激活MYC蛋白。
  • COQ2缺陷的骨髓瘤细胞对脂质过氧化激活剂RSL3的敏感性增加。
  • 4-CBA增强原代CD138+骨髓瘤细胞和异种移植小鼠模型对RSL3的敏感性。
  • 4-CBA与RSL3联合处理诱导硼替佐米耐药骨髓瘤细胞死亡。

临床怎么用

  • 作者认为靶向COQ2可能是有前景的骨髓瘤治疗策略。
  • 作者认为COQ2通过MEK/ERK/MYC轴促进细胞增殖和肿瘤生长。
  • 作者认为靶向COQ2可增强骨髓瘤细胞对铁死亡的敏感性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is the second most common malignant haematological disease with a poor prognosis. The limit therapeutic progress has been made in MM patients with cancer relapse, necessitating deeper research into the molecular mechanisms underlying its occurrence and development. A genome-wide CRISPR-Cas9 loss-of-function screening was utilized to identify potential therapeutic targets in our research. We revealed that COQ2 plays a crucial role in regulating MM cell proliferation and lipid peroxidation (LPO). Knockout of COQ2 inhibited cell proliferation, induced cell cycle arrest and reduced tumour growth in vivo. Mechanistically, COQ2 promoted the activation of the MEK/ERK cascade, which in turn stabilized and activated MYC protein. Moreover, we found that COQ2-deficient MM cells increased sensitivity to the LPO activator, RSL3. Using an inhibitor targeting COQ2 by 4-CBA enhanced the sensitivity to RSL3 in primary CD138+ myeloma cells and in a xenograft mouse model. Nevertheless, co-treatment of 4-CBA and RSL3 induced cell death in bortezomib-resistant MM cells. Together, our findings suggest that COQ2 promotes cell proliferation and tumour growth through the activation of the MEK/ERK/MYC axis and targeting COQ2 could enhance the sensitivity to ferroptosis in MM cells, which may be a promising therapeutic strategy for the treatment of MM patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Li M, Zhang CL, Zhou DS, et al. Identification of COQ2 as a regulator of proliferation and lipid peroxidation through genome-scale CRISPR-Cas9 screening in myeloma cells. Br J Haematol. 2024. PMID: 38462771. doi:10.1111/bjh.19375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。